The efficacy of Ruxolitinib tablets

Ruxolitinib is a drug used to treat moderate or high-risk myelofibrosis, a myeloproliferative neoplasm that affects the bone marrow; it is also used to treat polycythemia vera and steroid-refractory acute graft-versus-host disease when there is an inadequate response to or intolerance to hydroxyurea. Ruxolitinib tabletsis aJanus kinase inhibitor.

Ruxolitinib works by blocking a group of enzymes known as Janus kinases (JAKs), which are involved in the production and growth of blood cells. In myelofibrosis and polycythemia vera, there is too much JAK activity, causing abnormal production of blood cells. These blood cells migrate to organs, including the spleen, causing the organs to enlarge. JAK is also involved in the development and activation of blood cells that play a role in graft-versus-host disease. Reductions in spleen size and symptoms in patients taking ruxolitinib tablets are clinically important, and patients' quality of life is improved, and ruxolitinib tablets have also been shown to reduce symptoms.

Ruxolitinib tabletsThe original drug has been launched in China and is included in the scope of Class B medical insurance. It is limited to patients who meet the indications. Specification The price of each box of 5mg*60 tablets may be around RMB 3,000. The Turkish version of ruxolitinib tablets listed overseas, Specifications20mg*56 tablets, may be priced around RMB 8,000 per box (the price may fluctuate due to exchange rates). There are also ruxolitinib tablets produced in other countries. For example, the price of 5mg*50 tablets produced by Bangladesh Yaopin International may be around 1,400 yuan per box (the price may fluctuate due to exchange rates). Its pharmaceutical ingredients are basically the same as those of domestic and foreign original drugs.